Microsatellite Instability and DNA Mismatch Repair Protein Deficiency in Lynch Syndrome Colorectal Polyps by Yurgelun, Matthew B. et al.
Microsatellite Instability and DNA Mismatch Repair Protein
Deficiency in Lynch Syndrome Colorectal Polyps
Matthew B. Yurgelun1, Ajay Goel2, Jason L. Hornick3, Ananda Sen4, D. Kim Turgeon4,9,
Mack T. Ruffin IV4,9, Norman E. Marcon5,9, John A. Baron6,9, Robert S. Bresalier7,9, Sapna
Syngal3,8,9, Dean E. Brenner4,9,10, C. Richard Boland2, and Elena M. Stoffel3,4,8,9
1Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, USA
2Baylor University Medical Center, Baylor Research Institute and Charles A. Sammons Cancer
Center, Dallas, Texas, 75246, USA
3Brigham and Women’s Hospital, Boston, Massachusetts, 02115, USA
4University of Michigan Medical Center, Ann Arbor, Michigan, 48109, USA
5The Wellesley Site-St. Michael’s Hospital, Toronto, Ontario, Canada
6University of North Carolina, Chapel Hill, North Carolina, 27599, USA
7University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA
8Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, USA
9Great-Lakes New-England Clinical Epidemiology and Validation Center of the Early Detection
Research Network (GLNE-EDRN)
10VA Medical Center, Ann Arbor, MI 48105
Abstract
Colorectal cancers associated with Lynch syndrome (LS) are characterized by deficient DNA
mismatch repair (MMR) function. Our aim was to evaluate the prevalence of microsatellite
instability (MSI) and loss of MMR protein expression in LS-associated polyps. Sixty two
colorectal polyps – 37 adenomas (APs), 23 hyperplastic polyps (HPs), and 2 sessile serrated
polyps (SSPs) – from 34 subjects with germline MMR gene mutations were tested for MSI using a
single pentaplex PCR for five mononucleotide repeat microsatellite markers, and also for
expression of MLH1, MSH2, MSH6, and PMS2 proteins by immunohistochemistry (IHC). High-
level MSI (MSI-H) was seen in 15/37 (41%) APs, 1/23 (4%) HPs, and 1/2 (50%) SSPs. Loss of
MMR protein expression was seen in 18/36 (50%) APs, 0/21 HPs, and 0/2 SSPs. APs ≥8 mm were
significantly more likely to demonstrate MSI-H (OR = 9.98, 95% CI: 1.52-65.65, p = 0.02) and
deficient MMR protein expression (OR = 3.17, 95% CI: 1.20-8.37, p = 0.02) compared with those
<8 mm. All (6/6) APs ≥10 mm demonstrated both MSI-H and loss of MMR protein expression by
IHC. Our finding that the prevalence of MMR deficiency increases with the size of APs suggests
that loss of MMR function is a late event in LS-associated colorectal neoplasia. Although testing
large APs may be of value in the diagnostic evaluation of patients with suspected LS, the absence
of an MMR deficient phenotype in an adenoma cannot be considered strong evidence against LS,
as it is with colorectal carcinomas.
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Introduction
Lynch syndrome (LS), formerly known as hereditary nonpolyposis colorectal cancer
(HNPCC), is the most common inherited colorectal cancer (CRC) syndrome.(1) CRC is the
most common LS-associated malignancy(2) and approximately 2-3% of all CRC diagnoses
can be attributed to LS.(2, 3) In the absence of risk-reducing interventions, individuals with
LS have an estimated 70% lifetime risk of CRC,(3, 4) with many of these tumors developing
at early ages and demonstrating accelerated malignant transformation.
Lynch syndrome results from germline mutations in one of the genes involved with DNA
mismatch repair (MMR): MLH1, MSH2, MSH6, PMS2, or EPCAM/TACSTD1.(5-11)
Functional impairment of the DNA MMR system results in the accumulation of insertion/
deletion lesions at loci of DNA repeat sequences termed microsatellites, thereby producing a
phenotype known as microsatellite instability (MSI).(12, 13) High-level microsatellite
instability (MSI-H) is seen in nearly 90% of LS-associated CRCs, compared to only 15% of
sporadic CRCs.(11, 14-17) Analyzing CRCs for MSI and deficient MMR protein expression
by immunohistochemical (IHC) staining has become a useful strategy for identifying
patients who should undergo genetic evaluation for LS(2, 15, 16, 18) and some have even
advocated for the routine testing of all CRCs.(17, 19)
Intensive colonoscopic surveillance is effective in reducing CRC-related morbidity and
mortality in patients with LS.(20, 21) Therefore, establishing the diagnosis can help ensure
that individuals at risk undergo colonoscopies at 1-2 year intervals, as recommended by
evidence-based expert guidelines.(22) Given the importance of identifying patients at risk
for LS prior to the diagnosis of CRC, it would be useful to know whether testing for
evidence of MMR deficiency is informative in premalignant lesions.
The aim of this study was to determine the prevalence of MSI and loss of MMR protein




Individuals with known pathogenic germline mutations in one of the DNA MMR genes
(MLH1, MSH2, MSH6, PMS2, or EPCAM/TACSTD1) were identified from registries at
three U.S. cancer centers (Dana-Farber Cancer Institute, Boston, MA; University of
Michigan Comprehensive Cancer Center, Ann Arbor, MI; MD Anderson Cancer Center,
Houston, TX). Subjects who had available colorectal polyp tissue from previous endoscopic
or surgical resections were considered for analysis. Approximately half of the MMR
mutation carriers with colorectal polyps had participated in a randomized trial comparing
colorectal polyp detection using chromoendoscopy and conventional colonoscopy exams
(23) and the remaining subjects had colorectal polyps removed during colonoscopies
performed as part of their clinical care. Subject gender, age at the time of polyp removal,
and MMR gene known to be mutated were recorded.
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Each colorectal polyp was classified as an adenomatous polyp (AP), hyperplastic polyp
(HP), or sessile serrated polyp (SSP), based on the original pathology report issued as part of
the patients’ routine clinical care, and reviewed by a gastrointestinal pathologist (J.L.H.) to
confirm the histologic classification. Polyp size in millimeters was obtained from pathology
reports. Polyp location within the colon was obtained from endoscopic and pathology
reports; polyps located in the cecum through the transverse colon proximal to the splenic
flexure were considered to have a proximal location; polyps from the splenic flexure through
the rectum were considered to have a distal location.
Microsatellite Instability Analysis
DNA was microdissected from paraffin-embedded tissue blocks for microsatellite instability
(MSI) testing. For each sample, a pentaplex polymerase chain reaction (PCR) was
performed targeting five mononucleotide repeat microsatellite markers (BAT-25, BAT-26,
NR-21, NR-24, and NR-27), as has been previously described.(24) This panel has recently
been shown to have superior sensitivity and specificity for detecting LS-associated CRCs
compared to the National Cancer Institute (NCI)-endorsed panel, which uses two
mononucleotide markers (BAT-25 and BAT-26) and three dinucleotide markers (D2S123,
D17S250, and D5S346).(18, 25) Unlike the NCI-endorsed panel, this pentaplex PCR can be
performed as a single reaction and does not require simultaneous analysis of corresponding
germline DNA from subjects.(24) Polyps were considered to have high-level microsatellite
instability (MSI-H) if ≥40% of the markers that gave results were unstable. When 1-39% of
the markers that gave results were unstable, polyps were considered to have low-level
microsatellite instability (MSI-L); polyps were considered microsatellite stable (MSS) when
no instability was detected in any of the markers.
DNA Mismatch Repair Immunohistochemical Analysis
Immunohistochemistry was performed following pressure cooker heat-induced epitope
retrieval (0.01 M citrate buffer, pH 6.0) on 4-μm thick formalin-fixed paraffin-embedded
tissue sections using mouse anti-MLH1 monoclonal antibody (1:100 dilution; clone ES05;
Novocastra, Newcastle Upon Tyne, U.K.), mouse anti-MSH2 monoclonal antibody (1:150
dilution; clone FE11; Calbiochem, Gibbstown, NJ), mouse anti-PMS2 monoclonal antibody
(1:50 dilution; clone MRQ-28; Cell Marque, Rocklin, CA), and mouse anti-MSH6
monoclonal antibody (1:400 dilution; clone PU29; Novocastra), and the Envision Plus
detection system (Dako, Carpinteria, CA). Expression of MLH1, MSH2, PMS2, and MSH6
was assessed in a blinded fashion by one of the authors (J.L.H.) and was scored as “intact”
or “deficient” in lesional cells (epithelial cells in the polyp). The overall IHC status of a
polyp was classified as “abnormal” if the polyp had deficient expression of the MMR
protein whose gene was known to be mutated in that particular patient. Polyps that had
intact IHC staining for the MMR protein known to be mutated in that particular patient (as
well as all other MMR proteins that gave interpretable IHC results) were deemed to have
“intact” IHC. Non-neoplastic cells (epithelial cells, lymphocytes, and stromal cells) served
as an internal positive control in all tissue sections.
MSI and IHC Concordance
For all polyps in which results for both MSI and MMR protein expression by IHC were
available, concordance between the two tests was assessed. Polyps were classified as having
concordant results if they had intact IHC and were MSS/MSI-L or if they had abnormal IHC
and were MSI-H.
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Adenoma size was examined as both a continuous and dichotomous variable (<8 mm, and
≥8 mm). Subject age at the time of polypectomy was studied as a continuous variable. Other
characteristics – including subject gender, polyp location, and germline MMR gene mutation
– were examined as categorical variables. MMR gene mutation was included in the model as
a dichotomous variable (MSH2 mutation vs. other) to overcome model convergence
difficulties. A generalized estimating equations approach with an exchangeable working
correlation matrix was adopted to account for clustering within subjects. Separate models
were fit using polyp size either as a continuous or a dichotomous variable. The validity of
using a linear polyp size variable in the regression model was confirmed from a rough linear
pattern in an added variable plot in which the residuals from the logistic regression model
without polyp size as a covariate was plotted against the residuals from a linear model with
polyp size as a dependent variable and the same covariates as in the logistic regression
model. A similar logistic regression analysis was also carried out to model the likelihood of
observing a specific MSI status (MSI-H vs. MSI-L/MSS). The regression analysis was




Sixty two colorectal polyps from 34 subjects with known pathogenic germline mutations in
one of the DNA MMR genes (MLH1, MSH2, MSH6, or PMS2, or EPCAM/TACSTD1)
were identified (mean of 1.8 polyps per subject; range 1-6). Fourteen (41%) of the subjects
were men; subjects’ median age at the time of first polyp removal was 47.5 years (range
23-67). Twenty-one (62%) subjects had germline mutations in MSH2, 11 (32%) in MLH1,
and 2 (6%) in MSH6.
Adenomatous Polyps
Thirty-seven of the polyps from 21 subjects were identified as APs. Fifteen (41%) were
from males and 18 (49%) were from subjects who were ≥50 years of age at the time of
polypectomy. Mean size of APs was 5.0 mm (range 1-15 mm); 22 (59%) were <5, 7 (19%)
were between 5-9 mm, and 6 (16%) ≥10 mm. Sixteen (43%) were located in the proximal
colon. Further details regarding subject demographics and polyp characteristics and are
presented in Table 1A.
MSI analysis was performed on all 37 APs. Fifteen (41%) demonstrated MSI-H, 3 (8%)
were MSI-L, and the remaining 19 (51%) were MSS. MSI-H was seen in 6/6 (100%) APs
≥10 mm, 2/7 (29%) APs 5-9 mm, and 7/22 (32%) APs <5 mm. The logistic regression
model with the dichotomous MSI status as outcome (MSI-H vs. MSI-L/MSS) showed a
significant association between MSI and AP size, with larger (≥8 mm) APs having a
significantly higher likelihood of demonstrating MSI-H than smaller (<8 mm) ones
(OR=9.98, 95% CI: (1.52, 65.65), p=0.02). There was also a significant association between
MSI-H and subject age, with APs diagnosed at older ages having significantly higher odds
of being MSI-H (OR=1.18, 95% CI: (1.09, 1.28), p < 0.0001). Polyp size as a continuous
variable remained a statistically significant predictor of MSI status (OR =1.19, 95% CI:
(1.02, 1.39), p=0.025). The significant association between age and MSI status was also
retained in the model using continuous polyp size (OR per mm = 1.17, 95% CI: (1.09, 1.25),
p < 0.0001).
Only 1 (25%) of 4 APs from MSH6 mutation carriers was MSI-H, compared to 33% and
48% from MLH1 and MSH2 mutation carriers respectively; this difference, however, was
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not statistically significant (p=0.26). There was no significant association between MSI
status and subject gender (Table 3).
Conclusive MMR IHC results were available on 36 APs. Thirty (83%) had sufficient tissue
to give conclusive results for all four MMR proteins, 5 (14%) had results on three of the four
MMR proteins, and 1 (3%) AP from an MSH2 mutation carrier had results for MLH1 and
MSH2 staining only. In total, 18 (50%) of the 36 APs were classified as having abnormal
IHC results. Abnormal IHC was observed in 6/6 (100%) APs ≥10 mm in size, 4/7 (57%)
APs 5-9 mm, and 8/21 (38%) APs <5 mm. In the logistic regression model, the prevalence
of abnormal MMR IHC was significantly associated with AP size, with larger (≥8 mm) APs
having a significantly higher likelihood of demonstrating abnormal IHC (OR=3.17, 95% CI:
(1.20, 8.37), p=0.02) compared to smaller (<8 mm) APs. Size as a continuous predictor lost
significance, but only marginally (OR per mm = 1.08, 95% CI: (0.996, 1.16), p=0.06).
Among the 12 APs from MLH1 carriers, 8 (67%) had absent MLH1 staining (Figure 1A), 7
of which also demonstrated absence of PMS2 staining. Of the 20 APs from MSH2 mutation
carriers, 10 (50%) had absent MSH2 staining (Figure 1B), 9 of which also demonstrated
absence of MSH6 staining (the remaining one had very weak MSH6 staining and absent
MSH2 staining). None of the 4 APs from MSH6 mutation carriers had abnormal MMR IHC,
compared with 67% and 50% of APs from MLH1 and MSH2 mutation carriers,
respectively; this, however, did not result in any statistical significance. There was no
significant association between MMR IHC results and subject gender or age, although the
data suggested a nonsignificant trend toward higher odds of abnormal IHC with increasing
age (Table 3).
Thirty six of the 37 APs had results for both MSI and MMR IHC (one MSI-H AP had
insufficient tissue for IHC analysis). Thirteen of the 14 APs with MSI-H also had deficient
MMR protein expression by IHC. In comparison, only 13 of 18 APs with deficient MMR
protein expression by IHC also demonstrated MSI-H. Thus, 6 (17%) of the 36 APs had MSI
and IHC results that were discordant. All six of the APs with discordant results were from
subjects under the age of 50 and ranged from 2-8 mm in size. Only one AP was MSI-H with
intact MMR protein expression, and this was a proximally-located 2 mm adenoma from an
MSH6 mutation carrier.
Overall, 20/37 (54%) APs demonstrated a phenotype of MMR deficiency with MSI-H,
abnormal IHC, or both. All (100%) six of the APs ≥10 mm in size were both MSI-H and had
deficient MMR protein expression by IHC.
Hyperplastic and Sessile Serrated Polyps
Twenty-three polyps from 19 subjects were identified as HPs. Six (26%) of the 23 HPs came
from male subjects and 8 (35%) were from patients who were ≥50 years old. Size data were
available on all 23 HPs, with a mean of 3.0 mm (range 1-7 mm); 21 (91%) were <5 mm,
while the remaining 2 (9%) were between 5-9 mm. Four (17%) of the 23 HPs were located
in the proximal colon. Further details regarding subject demographics and polyp
characteristics are presented in Table 1B.
MSI analysis was performed on all 23 HPs. MSI-H was seen in 1/23 (4%) and 3/23 (13%)
were MSI-L; the remaining 19/24 (83%) HPs were MSS. There was no significant
association between MSI status and subject gender, age, mutated MMR gene, HP location,
or HP size. DNA MMR IHC results were available on 21 HPs; 100% had intact MMR
protein expression by IHC. Two polyps were SSPs and came from 2 different subjects. One
10 mm SSP from an MSH2 mutation carrier was MSI-H and the other 5 mm SSP from an
Yurgelun et al. Page 5













MLH1 mutation carrier was MSS. Both of the SSPs had intact IHC staining for all four
MMR proteins (Table 1C).
Discussion
Overall, we detected an MMR deficient phenotype in approximately half of all adenomas
from confirmed MMR mutation carriers, a prevalence that is much lower than what is seen
in LS-associated CRC.(14-16) The likelihood of having an MMR deficient phenotype is
significantly associated with increasing adenoma size, and 6/6 large (≥10 mm) adenomas
exhibited both MSI-H and abnormal IHC Neither subject gender, younger subject age, nor
proximal colon location showed a significant association with either MSI status or IHC
results for LS-associated APs. Of note, none of the APs from MSH6 mutation carriers had
abnormal MMR protein expression by IHC. Of the LS-associated HPs, only 1 of 23 was
MSI-H and none demonstrated abnormal MMR protein expression.
Adenomatous polyps (APs) are believed to be the precursor lesions for LS-associated CRC,
making them a potential target for diagnostic testing.(26, 27) Prior studies attempting to
define the prevalence of MSI and deficient MMR protein expression in LS-associated APs
have used various criteria for defining LS and have reported rates of MSI-H and abnormal
IHC ranging from 33-89% and 25-82%, respectively.(27-34)
Our findings add to the existing literature by demonstrating a significant association
between the likelihood of an MMR deficient phenotype and increasing polyp size in LS-
associated APs. Although the overall prevalence of both MSI-H and deficient MMR protein
expression by IHC in our study was lower than in prior reports,(27, 34) the comparatively
small size of the APs (mean size 5.0 mm) removed from subjects undergoing intensive
colonoscopic surveillance may account for this difference. Our observation that APs from
MSH6 mutation carriers showed universally intact MMR IHC staining reinforces previous
reports that colorectal neoplasms in MSH6 mutation carriers have a relatively mild MMR
deficient phenotype.(9, 35) This phenomenon can potentially be explained by prior work,
which demonstrated that isolated loss of MSH6 gene function is not, by itself, sufficient to
lose MMR activity due to the partially overlapping function of MSH3.(36)
Our study has several strengths. This was a multicenter study that included only subjects
who were confirmed to carry a pathogenic germline mutation in one of the DNA MMR
genes. We also obtained both MSI and MMR IHC results on nearly all of our polyps,
thereby allowing us to describe the concordance between the two tests. Furthermore, ours is
the first study of its kind to include an extensive analysis of HPs from subjects with
genetically-confirmed LS.
We recognize that our study has several limitations. While the number of MMR mutation
carriers is large compared with other published studies, the overall small number of polyps
examined limits the statistical power of our analyses. We examined only 4 APs from 2
subjects with MSH6 mutations and no polyps from PMS2 or EPCAM/TACSTD1 mutation
carriers, thereby limiting the conclusions that can be made about MSI and MMR IHC testing
in these subjects. Likewise, the small number of SSPs in our study precludes us from
commenting on their role in LS-associated neoplasia. Our study only included subjects with
confirmed LS and thus does not provide any information regarding the utility of MSI and
MMR IHC testing of unselected colorectal polyps, although prior data suggest that the rate
of MMR deficiency in sporadic APs is extremely low (<2%).(37-39) Since we did not
include polyps from non-LS control subjects, we are unable to define the specificity,
positive predictive value, or negative predictive value of MSI and MMR IHC for detecting
cases of LS.
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Our findings have diagnostic implications in that they suggest that MMR IHC testing could
provide useful information in the evaluation of patients with suspected LS who have large
adenomas, but no cancer tissue available for testing. Absent expression of one or more DNA
MMR proteins would provide justification for formal genetic evaluation for LS with the
added benefit of identifying which genes should be targeted for germline sequencing. It is
important to recognize, however, that the finding of intact MMR function in such adenomas
cannot be considered evidence against a diagnosis of LS.
We believe that our findings also provide important insight into the biology of LS-associated
colorectal neoplasia. Although all of the subjects in our study were confirmed carriers of a
pathogenic germline mutation in a DNA MMR gene and thus had a “first hit” monoallelic
loss of DNA MMR gene expression at baseline, only about half of the LS-associated APs in
our study demonstrated an MMR deficient phenotype – a phenomenon that requires biallelic
inactivation of MMR gene function. We would thus hypothesize that the early steps in LS-
associated colorectal neoplasia are likely similar to those in sporadic AP formation with
abrogation of WNT signaling via biallelic inactivation of the APC gene or through
mutations in β-catenin.(40) Our observation of high rates of deficient MMR protein
expression in large APs, along with the well-described high rates of MMR deficiency in LS-
associated CRCs(1, 2, 15) would suggest that the “second hit” somatic loss of MMR activity
is a relatively late event in LS-associated neoplasia.
The observation that MSI analysis is even less sensitive than DNA MMR IHC in small (<8
mm) LS-associated APs further supports this hypothesis. The phenotype of MSI is
determined by evaluating markers that are highly-sensitive “hotspots” which, when mutated,
give an accurate reflection of deficient DNA MMR function.(18, 24, 25, 40) In and of
themselves, however, mutations at these particular sequences are probably of minimal
biologic relevance and are instead simply indicators of an MMR deficient phenotype. MSI-
induced carcinogenesis instead occurs via biallelic mutations in the coding microsatellites of
genes that regulate cell proliferation (such as TGFβR2) and apoptosis (such as BAX).(40,
41) Thus, we would expect that mutations seen in the pentaplex markers are passengers and
relatively late phenomena seen in more advanced neoplasms, occurring only after the
acquisition of biallelic loss of DNA MMR function.
In summary, large (≥8 mm) LS-associated APs demonstrate a phenotype of deficient DNA
MMR function at a frequency comparable to what is seen in LS-associated CRCs, whereas
small (<8 mm) APs are significantly less likely to exhibit MSI-H and/or abnormal DNA
MMR protein expression. Our findings provide important insight into LS-associated
carcinogenesis and imply that loss of DNA MMR function is likely to be a relatively late
event in LS-associated neoplasia. Our data suggest that the finding of MMR deficiency in
APs can have clinical utility, particularly in the evaluation of patients with suspected LS
who have not developed colorectal adenocarcinoma. Although the absence of an MMR
deficient phenotype would not be sufficient to exclude a diagnosis of LS, the finding of
MSI-H and/or abnormal MMR expression in an AP from a patient with a concerning family
history could provide justification for formal genetic evaluation and germline sequencing.
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(A) An adenoma from a subject with a germline mutation in MLH1 shows loss of MLH1
protein expression in the adenomatous epithelium by immunohistochemistry. Note the intact
nuclear staining in non-neoplastic epithelial cells of the lower crypts (original magnification
x200). (B) An adenoma from a subject with a germline mutation in MSH2 shows loss of
MSH2 protein expression in the adenomatous epithelium (original magnification x200).
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Table 3
Factors predicting for MSI-H and deficient mismatch repair (MMR) protein expression in Lynch syndrome
adenomas







Subject Sex (Reference: Male) 0.14 (0.01, 1.42) 0.33 (0.05, 2.18)
Subject Agec 1.18 (1.09, 1.28) 1.07 (0.99, 1.15)
Subject’s Germline Mutation
(Reference: MSH2 mutation) 3.53 (0.39, 32.3) 1.39 (0.23, 8.36)
Adenoma Sizec 1.19 (1.02, 1.39) 1.08 (0.996, 1.16)
Adenoma Sized (Reference: <8
mm)
9.98 (1.52, 65.65) 3.17 (1.20, 8.37)
a
Modeling the odds of observing MSI-H versus MSI-L/MSS.
b
Modeling the odds of observing abnormal MMR IHC versus intact MMR IHC.
c
Subject age and adenoma size studied as continuous variables.
d
Adenoma size as a dichotomous variable.
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